Pyxis Oncology Inc at RBC Capital Markets Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Leonid Timashev - RBC Capital Markets - Analyst : And just to start off, presented data, which we'll get into, but maybe just for a second to zoom out bigger picture. Can you remind us what's special about MICVO, maybe the target, the unique optimized payload linker structure?

Question: Leonid Timashev - RBC Capital Markets - Analyst : Really helpful overview. Thank you. So last year, you guys presented the first look at efficacy data for MICVO. Obviously, there was some mixed reactions to the data, but I guess what's the key takeaway from that data for you guys with respect to the responses you've seen and sort of how it validates the path forward?

Question: Leonid Timashev - RBC Capital Markets - Analyst : Yeah, that makes sense. I think one of the most frequent questions we heard post the data was actually on safety. So there was a patient death. But can you talk about maybe the overall tolerability of the ADC candidate, what you saw coming out of that trial and maybe as we look forward to the next cuts of data, if there's any specific adverse events that we should be (multiple speakers) for? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 21, 2025 / 6:05PM, PYXS.OQ - Pyxis Oncology Inc at RBC Capital Markets Global Healthcare Conference

Question: Leonid Timashev - RBC Capital Markets - Analyst : Got it. On the efficacy side, I mean, you mentioned the 50% response rate. How does that compare to what's currently in the treatment landscape for head and neck?

Question: Leonid Timashev - RBC Capital Markets - Analyst : Yeah. Maybe one last question on the data you presented last year. It was obviously, as you mentioned, a broader basket study. Head and neck wasn't the only thing you guys looked at. So among the other tumor types, I guess, are there other signals you guys think are interesting that are worth pursuing maybe after head and neck?

Question: Leonid Timashev - RBC Capital Markets - Analyst : I wanted to touch on some preclinical data that you presented at AACR, including on tumor signatures. Can you talk about sort of how it informs the mechanism more broadly and also what you've learned from that data and potentially being able to identify who might be most responsive or what tumors might be most responsive?

Question: Leonid Timashev - RBC Capital Markets - Analyst : I want to spend a few minutes talking about the next set of trials that you're running. So with respect to the monotherapy data in second and third line, I guess, how many patients' worth of data should we be thinking about? Do you have a sense of what the timing might be for that data? And I know you sort of alluded to it, but, what you'd like to see in terms of response?

Question: Leonid Timashev - RBC Capital Markets - Analyst : Got it. On the combination study, how do you think about teasing out the response rate of Keytruda?

Question: Leonid Timashev - RBC Capital Markets - Analyst : Got it. You mentioned that the PD1 combo study is a dose ranging study as well. So how are you thinking about that 3.6 to 5.4 milligram per kilogram target dose for monotherapy as it translates into the combo? I mean, do you think that's still going to be the right range? Is it possible to push dose higher just based on what you saw in the monotherapy? On the other hand, is there any potential and overlapping toxicity that you're watching for?

Question: Leonid Timashev - RBC Capital Markets - Analyst : Got it. We only have ten seconds left, but wanted to ask what the reception of the data has been in the physician community? How excited the sites are to keep enrolling in the study, add new patients, just as a contrast to maybe what we're seeing elsewhere?